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Abstract
Background: Phyllodes tumors are biphasic fibroepithelial neoplasms of the breast. While the
surgical management of these relatively uncommon tumors has been addressed in the literature,
few reports have commented on the surgical approach to tumors greater than ten centimeters in
diameter – the giant phyllodes tumor.
Case presentation: We report two cases of giant breast tumors and discuss the techniques
utilized for pre-operative diagnosis, tumor removal, and breast reconstruction. A review of the
literature on the surgical management of phyllodes tumors was performed.
Conclusion: Management of the giant phyllodes tumor presents the surgeon with unique
challenges. The majority of these tumors can be managed by simple mastectomy. Axillary lymph
node metastasis is rare, and dissection should be limited to patients with pathologic evidence of
tumor in the lymph nodes.
Background
The phyllodes tumor, originally described by Johannes
Muller in 1838, has presented a diagnostic and treatment
dilemma for physicians since its original description.
Classically, the name cystosarcoma phyllodes was
assigned because of the tumor's fleshy appearance and
tendency to contain macroscopic cysts. The term, how-
ever, is a misnomer as these tumors are usually benign.
Phyllodes tumor is the currently accepted nomenclature
according to the World Health Organization (WHO).
While the surgical management of the phyllodes tumor
has been addressed many times in the literature, few
reports have specifically commented on the giant phyl-
lodes tumor, an entity that presents the surgeon with sev-
eral unique management problems. The median size of
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tumors grow larger than 10 cm, the arbitrary cut off point
for the designation as a giant tumor. These tumors can
reach sizes up to 40 cm in diameter [2]. We will review
two recent cases at The Ohio State University that had pre-
operative diagnoses of giant phyllodes tumor and discuss
the surgical techniques employed, including the recon-
structive options.
Methods
We performed a retrospective chart review of patients
treated for giant phyllodes tumors at The Ohio State Uni-
versity Medical Center between the years 1999–2001. A
Medline search for articles in the English language using
the key words phyllodes tumor and cystosarcoma phyl-
lodes was also conducted.
Case presentation
Case 1
Patient A is a 64 year old white female who presented with
a large right breast mass. The mass had been present for at
least 2 years, and the breast was swollen, streaked with
grey and blue, and mildly tender. There was no personal
or family history of breast cancer. Her past medical history
was significant for a hysterectomy and oophorectomy at
46 years of age. Her first menstrual period was at age 13,
and she had never been pregnant.
Physical exam revealed a well-nourished female with an
obvious mass of the right breast. The mass measured 36 ×
30 cm at the time of presentation. The skin of the breast
was blue at the apex of the mass, and the nipple was mas-
sively enlarged and excoriated (Fig 1). On initial presenta-
tion, there was no evidence of skin breakdown, but by the
time of surgery, the patient had experienced loss of skin
integrity. The contralateral breast was of normal size, with
no significant masses on palpation. There was no palpable
adenopathy in either of the axillary basins.
Fine needle aspiration was performed during the initial
visit and revealed highly atypical cells suspicious of a
malignant neoplasm. Core tissue biopsy showed mixed
epithelial-stromal proliferation suggestive of a phyllodes
tumor. CT scans of the chest, abdomen, and head showed
no evidence of distant metastasis but did suggest invasion
of the tumor into the chest wall. For this reason, initial
surgical management only involved tumor resection, and
breast reconstruction was deferred.
Right simple mastectomy was performed. Superior and
inferior skin flaps were designed to allow skin approxima-
tion and closure after removal of the large tumor. These
flaps included skin directly overlying the tumor that
appeared normal (Fig 2). The superior flap was raised to
the level of the clavicle. Dissection revealed that the blood
supply to the tumor was derived largely from collateral
vessels arising from the skin. These vessels were large and
friable, yet easily managed using standard techniques. The
inferior flap was then raised, demonstrating tumor that
was partly adherent to the inferior aspect of the pectoralis
major muscle. No blood supply originated from the mus-
cle. A portion of the pectoralis major muscle was excised
with the tumor, and no invasion of deeper chest wall
structures was noted. No lymphadenopathy was appreci-
ated; therefore, an axillary lymph node dissection was not
pursued. Two #19 Blake drains were placed beneath the
superior and inferior flaps, followed by approximation of
the flaps and skin closure (Fig 3).
The pathologic findings of this procedure were consistent
with benign phyllodes tumor. The tumor measured 30.0
× 25.0 × 20.0 cm ex vivo. Microscopic sections demon-
strated large, simple ducts surrounded by a uniform,
Case 1: The mass measured 36 × 30 cm with the characteris-tic bluish discoloration of the skin with nipple excoriationFigure 1
Case 1: The mass measured 36 × 30 cm with the characteris-
tic bluish discoloration of the skin with nipple excoriation.
Case 1: Intra-operative photo revealing dissection of the tumor with n  inv s on of the deeper che t wallFigure 2
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tive for the tumor with a tumor-free zone that ranged from
0.3 to 1.0 cm (Fig 4E). The Ki67 proliferation index of the
tumor from patient A was 5 and 13 for the epithelial and
stromal component, respectively (Fig 4F). The epithelial
component Ki67 index from this specimen is typical of
adenomas, whereas the index of 13 for the stromal com-
ponent is consistent with benign yet brisk stromal prolif-
eration. Mitoses were less than 3 per 10 high power field.
Three axillary lymph nodes were present within the mas-
tectomy specimen, and none of these showed evidence of
malignancy. The patient is currently over 7 years post-sur-
gery and has shown no evidence of local recurrence or dis-
tant metastasis.
Case 2
Patient B is a 70 year old white female who presented with
a large left breast mass. The patient was unsure how long
the lesion had been present. Nonspecific findings consist-
ent with a fibroadenoma were noted in the same region
on a mammogram obtained 5 years previous to her pres-
entation. Her past medical history was significant for hys-
terectomy at age 52. She had no personal history of
cancer, although her family history was significant for
lung and pancreatic cancers. She had used an estrogen and
progesterone combination for hormone replacement in
the past, the duration of which was unclear.
On physical examination, the patient's left breast had a
multilobulated and relatively firm mass that measured
approximately 12 cm in diameter and essentially replaced
the entire breast. No cervical, supraclavicular, or axillary
lymphadenopathy was noted. The contralateral breast
showed no signs of a mass. Core tissue biopsy taken at the
time of presentation suggested a diagnosis of cellular
fibroadenoma or phyllodes tumor. Pre-operative CT scan
revealed a 7.5 × 11 cm mass in the anterior portion of the
breast, with no apparent mediastinal, lung, neck, or axil-
lary lymphadenopathy.
Left modified radical mastectomy with dissection of level
I and level II lymph nodes was performed. A right mast-
opexy was performed for purposes of symmetry. An ellip-
tical incision encompassing the entire mass and the
overlying skin was made. Collaterals in the skin supplied
the tumor, and no deep invasion was identified. The supe-
rior and inferior skin flaps included skin that had been
overlying the tumor. The tumor was excised along with
the pectoralis muscle fascia. Axillary dissection was under-
taken because of the presence of palpable level II nodes
intra-operatively. A tissue expander was placed before
final closure, as the patient desired reconstruction.
The pathologic findings of this procedure were consistent
with a benign phyllodes tumor. The tumor measured 10.0
× 8.0 × 5.0 cm ex vivo. Microscopic sections showed large
branching ducts surrounded by a uniform, bland stroma
(Fig 4D); areas of hyalinization and myxoid change were
rare. As with patient A, the margin of resection was nega-
tive for the tumor with a tumor-free zone that ranged from
over 0.3 to 1.0 cm (Fig 4E). The Ki67 proliferation index
of the tumor from patient B was 0.8 and 4 for the epithe-
lial and stromal component, respectively (Fig 4F). No sig-
nificant cytologic atypia or mitotic activity was noted.
Sixteen lymph nodes were obtained, all of which were
benign.
The patient had an unremarkable post-operative course
and was able to start tissue expansion 19 days after her
surgery. She had exchange of her tissue expander for a per-
manent implant 6 months after her mastectomy. She had
an uneventful recovery from these surgical procedures and
is currently 6 years post-surgery without complication.
Discussion
Phyllodes tumors are fibroepithelial neoplasms with epi-
thelial and cellular stromal components, the latter of
which represents the neoplastic process [3]. The presence
of an epithelial component differentiates the phyllodes
tumor from other stromal sarcomas. They make up 0.3 to
0.5% of female breast tumors [1] and have an incidence
of about 2.1 per million, the peak of which occurs in
women aged 45 to 49 years [4,5]. The tumor is rarely
found in adolescents and the elderly [6,7].
Case 1: Intra-operative photo after tumor resection with pl c ment of two #19 Blake drains under the superior and inferior flapsFigure 3
Case 1: Intra-operative photo after tumor resection with 
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Case 1: A) Large, simple ducts were surrounded by a uniform, bland stroma in this tumor, which measured 30.0 × 25.0 × 20.0 cm x vivoFigure 4
Case 1: A) Large, simple ducts were surrounded by a uniform, bland stroma in this tumor, which measured 30.0 × 25.0 × 20.0 
cm ex vivo. B) The tumor had negative margins of resection that ranged from 0.3 to 1.0 cm. C) The Ki67 proliferation index for 
the tumor from patient A was 5 for the epithelial component and 13 for the stromal component. Case 2: D) Large, branching 
ducts were surrounded by a uniform, bland stroma; areas of hyalinization and myxoid change were rare in this 10.0 x 8.0 x 5.0 
cm tumor. E) The tumor had negative margins of resection that ranged from 0.3 to 1.0 cm. F) The Ki56 proliferation index for 
the tumor from patient B was 0.8 for the epithelial component and 4 for the stromal component.
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defined, round, macrolobulated, and painless mass. There
are no pathognomonic mammographic or ultrasound fea-
tures. Hence the phyllodes tumor can be extremely diffi-
cult to differentiate from a fibroadenoma, which is
sometimes treated with a non-operative approach [3]. For
this reason, early diagnosis of the phyllodes tumor is cru-
cial so that the correct management of the tumor, which
often does include surgery, can be pursued as early as pos-
sible. This may also prevent the growth of phyllodes
tumors into giant ones, such as in the two cases described
in our report. In a series of 106 patients by Chua et al.,
71% of patients with a post-operative diagnosis of phyl-
lodes tumor had a presumptive diagnosis of fibroade-
noma at the time of surgery [8]. Another series showed a
pre-operative diagnosis of phyllodes tumors in only 10 to
20% of patients [1].
A variety of techniques have been utilized to improve the
pre-operative diagnosis of phyllodes tumors. Cole-Beuglet
et al. performed a retrospective study on 8 cases of histo-
logically proven phyllodes tumors that were evaluated by
mammography and ultrasound. They determined that
while certain ultrasound findings (low-level internal ech-
oes, smooth walls, good through transmission, and
smooth margined fluid-filled clefts in a predominantly
solid mass) may suggest a phyllodes tumor, there is no
consistent and reliable way to distinguish between phyl-
lodes tumors and other benign appearing tumors on
ultrasound or mammography [9]. In a recent review
examining the use of ultrasound in the diagnosis of phyl-
lodes tumors, Chao et al. identified three sonographic fea-
tures that are characteristic of these tumors: well-
circumscribed, lobulated masses, heterogeneous internal
echo patterns, and a lack of microcalcifications [10]. In
addition, the authors shed light on the pre-operative dis-
tinction between fibroadenomas and phyllodes tumors.
Patients with fibroadenomas are generally younger than
the patients with phyllodes tumors; fibroadenomas have
a larger ratio of length to anteroposterior diameter; and
phyllodes tumors are generally larger than fibroadenomas
[10]. Another group investigated the possibility of estab-
lishing a pre-operative diagnosis of malignant or benign
phyllodes tumor through the use of color Doppler ultra-
sound. They concluded that although several ultrasono-
graphic features are characteristic of a malignant
phyllodes tumor, a histologic specimen should be
obtained for definitive diagnosis. The features that sug-
gested a malignant behavior were "marked hypoecho-
genicity, posterior acoustic shadowing, and higher values
of RI (resistance index), PI (pulsatility index), and Vmax
(systolic peak flow velocity) [11].
Another potentially useful diagnostic modality is mag-
netic resonance imaging (MRI). One article discussed the
use of MRI in characterizing benign phyllodes tumors.
Findings consistent with a benign phyllodes tumor
included a lobulated or polygonal shape with smooth
borders, cystic or septated features, and a gradual or rapid
pattern of time-signal intensity curve [12]. In a recent cor-
respondence, Cheung et al. discussed the pathological fea-
tures typical of phyllodes tumors and how they are
manifested in MRI. The authors went so far as to suggest
that the findings of "characteristic leafy internal morphol-
ogy, best shown on subtraction MRI, which highlighted
the enhancing cotyledonous solid portions within irregu-
lar blood-filled cystic spaces" are pathognomonic for a
phyllodes tumor [13].
Fine needle aspiration (FNA) has also been proposed as a
method to improve pre-operative diagnosis; however,
existing reports are not promising. Salvadori et al. found
the FNA to be diagnostic in only 4 of 30 cases [5]. Other
investigators have obtained similar results and have con-
cluded that FNA is usually non-diagnostic [14]. The diffi-
culty in diagnosing the phyllodes tumor by FNA is
compounded by the fact that it shares many cytologic fea-
tures with fibroadenoma [15,16].
Core tissue biopsy is an attractive alternative to FNA, and
several authors have suggested its use as a diagnostic pro-
cedure [8,17]. Interestingly, patient A had an initial non-
diagnostic FNA followed by a core tissue biopsy suggestive
of phyllodes tumor. Patient B had a core tissue biopsy
only, which provided a preliminary diagnosis of phyl-
lodes tumor. We believe that core tissue biopsy represents
the preferred means of pre-operative diagnosis for giant
breast tumors, and the histologic information gained
from this procedure is important in guiding surgical treat-
ment.
Phyllodes tumors are divided into benign, borderline, and
malignant histotypes based on the microscopic appear-
ance of the stromal component. Approximately 15 to 30%
of all phyllodes tumors are classified as malignant [5,18-
20]. Histologic appearance may not, however, correlate
with clinical behavior [17,18,20,21], as both malignant
and borderline tumors have been shown to be capable of
metastasizing. Reinfuss et al., using histotype criteria
developed by Azzopardi and Salvalori et al. [5], showed
that the histotype of the tumor was an independent prog-
nostic factor, with 5-year survivals of 95.7% for benign
tumors, 73.7% for borderline tumors, and 66.1% for
malignant tumors [2]. A study by Chaney et al., which
combined the benign and borderline tumors into a single
category, found 5-year survival rates of 91% for benign
tumors and 82% for malignant tumors. Ten-year survival
rates, however, dropped to 79% and 42%, respectively
[20]. A recent review and clinical follow-up of 33 cases
concluded that histopathological classification is thePage 5 of 8
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have failed to duplicate the correlation between histotype
and survival [17]. Metastasis is seen in 25 to 31% of malig-
nant tumors [1,20], but only in 4% of all phyllodes
tumors [5]. The most common sites for metastasis include
the lungs, bone, liver, and distant lymph nodes. Skin
involvement with tumor does not appear to be a predictor
of metastasis [23]. While the use of chemotherapy and
radiotherapy have shown promise in a few small trials,
their role in the treatment of metastatic phyllodes tumors
remains unproven. Hormonal therapy has also been
attempted, but with limited efficacy [20,24-26]. Patho-
logic factors associated with poor prognosis include
greater than 3 mitotic figures per high power field, infil-
trating margins, severe atypia, stromal overgrowth, stro-
mal component other than fibromyxoid, and tumor
necrosis [20,27-30]. Hawkins et al. reported a strong cor-
relation between stromal overgrowth and metastasis,
finding that 72% of tumors with stromal overgrowth will
eventually develop a metastasis [27]. Variables such as
age, symptom duration, and tumor growth rate are not of
prognostic value [27-30]. Phyllodes tumors do not typi-
cally metastasize via the lymphatics. About 20% of
patients have palpable axillary lymph nodes on presenta-
tion, but only 5% of these show histologic evidence of
metastasis upon pathologic examination. Of the phyl-
lodes tumors with a malignant histotype, up to 15% will
metastasize to the axilla [30]. In a 1972 retrospective
report, Kessinger et al. found that all metastatic lesions
described in the literature contained only stromal ele-
ments. No malignant epithelial elements were observed.
Since most sarcomas metastasize hematogenously, this
finding may explain why axillary metastasis is so rare [24].
Palpable lymphadenopathy is typically attributed to the
patient's immune response to tumor necrosis. The rare
patient who does have lymph node metastases tends to
have a poor prognosis [30]. Observing the rarity of lymph
node involvement, most authors have concluded that
removal of axillary lymph nodes is not warranted unless
there are palpable nodes [2,14,20,29,31,32]. Data regard-
ing sentinel lymph node biopsy in phyllodes tumors are
lacking. In patient A, 3 lymph nodes were included as part
of the mastectomy specimen. In patient B, palpable nodes
were present, therefore axillary dissection was performed.
However, neither patient showed evidence of tumor
spread to the lymph nodes. Theoretically, the axillary
nodal basin can be evaluated with sentinel lymph node
biopsy and subsequent frozen section in patients that
have clinically negative axillary nodes. However, patients
with giant phyllodes may have clinically enlarged axillary
lymph nodes that may be suspicious for metastatic dis-
ease. Sentinel lymph node biopsy may not be accurate in
these patients and the surgeon may be forced to proceed
with axillary lymph node dissection.
About 20% of phyllodes tumors would be considered
giant, or greater than 10 cm in maximum diameter [2]. As
mentioned before, the importance of this cut-off value has
been disputed. There is a continuing debate that exists
over the prognostic significance of tumor size
[23,26,28,32]. Thus, appropriate cut off values for tumor
size and associated prognosis have never been defined
[18]. There is also disagreement as to whether malignant
histology correlates with size. Some investigators show
that malignant tumors tend to be larger than benign ones
[8,26], while others have failed to duplicate this associa-
tion [2,20].
Surgical management of the phyllodes tumor has also
been a source of debate over the years. Some authors have
argued for simple mastectomy for phyllodes tumors
because of the risk of local recurrence after more conserv-
ative procedures [23,24,30,31]. However, studies have
shown no differences between breast conserving surgery
versus mastectomy in terms of metastasis-free survival or
overall survival, despite the higher incidence of local
recurrence that comes with breast conserving surgery [28].
Most experts currently advocate that surgeons obtain at
least 1 cm margins on primary excision or re-excision of a
tumor removed with close margins, as long as the tumor
to breast size will permit [1,2,5,8,14,17,20,30,33]. How-
ever, an excision with the required margins is often
impossible in giant phyllodes tumors such as the cases
reported here. Mastectomy should be reserved for larger
tumors [18,26] and should be considered in recurrent
tumors, especially of the malignant histotype [5,33]. Spe-
cifically, in cases in which phyllodes tumors have gone
undetected and developed into giant phyllodes tumors,
particular emphasis should be placed upon complete
removal of all visible tumor. Local recurrence in phyllodes
tumors has been associated with inadequate local excision
and various histological characteristics, including mitotic
activity, tumor margin, and stromal cellular atypia [34].
Because of the danger of recurrence that accompanies an
incomplete resection or a resection characterized by close
margins, the surgeon is often faced with the need for mas-
tectomy for phyllodes tumors that are greater than 10 cm.
Depending on the size of the breast and the location of
the phyllodes tumor, mastectomy may also be required
for tumors that are between 5 and 10 cm in diameter [35].
It should be emphasized that by the time a phyllodes
tumor becomes giant, there is no guarantee that the
remaining breast tissue has not been infiltrated by tumor
cells. Hence, the emphasis should be on complete extirpa-
tion of all visible tumor and breast tissue during mastec-
tomy. If all breast tissue has been removed, and all tumor
infiltrated soft tissues have been removed, then the tumor
is unlikely to recur locally.Page 6 of 8
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appropriate surgical procedure because of the large size of
the tumors when compared to the overall amount of
breast tissue. This procedure provides the best opportu-
nity for obtaining clear margins, thereby reducing the like-
lihood of tumor recurrence. We found that normal skin
overlying the tumor could be preserved with the expecta-
tion of close but negative margins. This approach permit-
ted skin closure without the need for split thickness skin
grafting in patient A and allowed placement of a tissue
expander in patient B. The ability to preserve the overlying
skin flaps is an important consideration in the surgical
management of giant phyllodes tumor as it generally
allows for a more satisfying cosmetic result.
Chest wall invasion appears to be an uncommon event
with phyllodes tumors. Reinfuss et al. reported that 2.4%
of phyllodes tumors in their series had clinically recorded
infiltration into the pectoralis major muscle [2]. Moore
and Kinne recommend extended excision of involved pec-
toralis muscle, followed by reconstruction of the chest
wall with Marlex mesh and methylmethacrylate [32].
Some have recommended the consideration of post-oper-
ative radiation for cases of chest wall infiltration [14].
Although patient A showed evidence of pectoralis major
muscle invasion, the involvement was not extensive and
was easily managed by excision of a portion of the muscle.
No invasion of deeper structures was noted in the other
case.
Foreknowledge of the location of the tumor's blood sup-
ply can be vital information when removing large tumors.
Little has been written on the subject with regard to giant
phyllodes tumors or breast cancers in general. A case
report by Jonsson and Libshitz documented the angio-
graphic pattern of a 25 cm phyllodes tumor. The tumor
was hypervascular with irregular and tortuous arteries.
Blood supply to the tumor was via one large and several
smaller perforating anterior branches of the internal
mammary, lateral thoracic, acromio-thoracic arteries, and
branches of the axillary artery [36]. We found that the
giant tumors in the present report derived the majority of
their blood supply from skin collaterals. Thus, the sur-
geon can expect the majority of blood loss during resec-
tion to come from the creation of the skin flaps. In this
situation, the surgeon need not routinely obtain an angi-
ogram.
In general, immediate breast reconstruction can be per-
formed at the time of mastectomy for phyllodes tumors
[14]. Mandel et al. reported a case in which subcutaneous
mastectomy was performed for a large phyllodes tumor,
followed by immediate implantation of a breast prosthe-
sis. They cite minimal interference with the detection of
recurrent lesions and the minimization of emotional dis-
tress as advantages to the procedure [37]. Orenstein and
Tsur described a similar case in an adolescent female in
which a silicon implant was placed under the pectoralis
major, where it would not impair the recognition of recur-
rent disease [38].
Local recurrence rates for phyllodes tumors are 15 to 20%
and are correlated with positive excision margins, rather
than with tumor grade or size [1,8,14,31]. Other studies
have shown a higher risk of local recurrence in borderline
and malignant tumors. In a series of 21 patients by Salva-
dori et al., 51 patients were treated with breast conserving
surgery (enucleations, wide excisions), and 14 of the
tumors recurred locally. In contrast, the 20 patients
treated with mastectomy (subcutaneous, modified radi-
cal, or radical) showed no evidence of local recurrence [5].
Importantly, there is no contraindication to immediate
reconstruction after mastectomy in cases of giant phyl-
lodes tumor, and this decision can be made solely based
upon patient peference [37,38].
Conclusion
In summary, management of the giant phyllodes tumor
presents the surgeon with unique challenges. Diagnosti-
cally, we believe that core tissue biopsy represents an
attractive means for pre-operative diagnosis and aids in
the differentiation of phyllodes tumors from fibroadeno-
mas. The majority of these tumors can be managed by
simple mastectomy. Axillary lymph node metastasis is
rare, and dissection should be limited to patients with
pathologic evidence of tumor in the lymph nodes. There
is no contraindication to immediate reconstruction after
mastectomy.
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